2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM REX-001, Placebo - Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM) | Phase 3 | Terminated | Ixaka Ltd | 49 | 2017-04-25 | 2023-03-16 |
| The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM REX-001, Placebo - Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM) | Phase 3 | Terminated | Ixaka Ltd | 3 | 2017-04-05 | 2021-05-07 |
Cardiovascular Diseases (2) · Chronic Limb-Threatening Ischemia (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Peripheral Arterial Disease (2)
Czechia (2) · Hungary (2) · Portugal (2) · Spain (2) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)